Trump Plans Tariffs on Generic Drugs, Creating Dilemma for Price-Cut Promises
Miles Bennett
Trump announced plans to impose tariffs on imported generics starting August 2028, aiming to bring manufacturing back to the U.S. But generics account for 90% of U.S. prescriptions and are overwhelmingly made overseas — tariffs risk raising prices and triggering shortages, directly clashing with his promise to cut drug costs.
Why target generic drugs with tariffs?
Generics fill roughly 90% of U.S. prescriptions, and the vast majority are produced overseas. This means → America's drug supply chain is deeply dependent on foreign manufacturing.
Trump's logic: give companies about two years to move production stateside before tariffs fully kick in, strengthening supply-chain self-reliance.
White House spokesperson Kush Desai said deregulation and other measures would make the transition "as smooth as possible," citing earlier brand-drug tariff negotiations as proof of execution.
What are critics worried about?
Advocacy group Public Citizen argued that while reducing reliance on a handful of suppliers makes sense, "the harms from tariffs will likely outweigh their supposed benefits." In plain terms = the goal is sound, but the tool may cause more damage than the problem itself.
Brookings fellow Marta Wosinska warned that building new plants in the U.S. could cost billions of dollars — many firms may lack the capacity or willingness to invest. "I worry many manufacturers will simply exit the market once tariffs hit," she said.
She added that a truly resilient supply chain "requires paying a higher price" — tariffs alone, without payment-system reform, will have limited effect.
What are drugmakers saying?
Some manufacturers have already said they will raise generic-drug prices in response to tariffs. This means → tariff costs will most likely be passed on to consumers.
Kathleen Jaeger, U.S. spokesperson for the Indian pharmaceutical alliance, said companies are willing to invest more in the U.S. — but they need market reform and long-term sourcing agreements, not tariffs.
In plain terms = drugmakers aren't refusing to come; they need a business environment that makes the math work. Tariffs alone don't provide that.
Will these tariffs actually take effect?
Capital Alpha managing partner Rob Smith noted the announcement mirrors Trump's approach to brand-name drugs — "consistent with the 'let's make a deal' pattern we've seen."
The brand-drug precedent: Trump announced 100% tariffs, but companies that struck price-cut deals with the government got exemptions. This reflects a pattern where tariffs function as an opening bid, not a final policy.
Generic-drug tariffs may follow the same path — headline threats first, then exemptions in exchange for concessions, and potentially never fully landing.
What does this mean for ordinary people?
The policy's core tension: reshoring manufacturing requires higher costs, while cutting drug prices requires lower costs. The two goals naturally pull in opposite directions.
If tariffs fully land and reshoring falls short, the most direct consequence is higher prices or shortages of generics — the drugs that fill nine out of ten U.S. prescriptions.
Put simply = whether this policy can simultaneously "bring the factories home" and "make drugs cheaper" is the ultimate test of its viability.
Content is for reference only, not financial advice.